• Most Popular
  • Most Shared

Bayer gets nod for leukemia drug as first-line use

Thu Sep 20, 2007 8:15am EDT

FRANKFURT, Sept 20 (Reuters) - The U.S. Food and Drug Administration (FDA) has approved expanded usage for Campath to include first-line treatment for adult leukemia, Bayer BAYG.DE and Genzyme Corp GENZ.0 said on Thursday.

The product is approved to treat B-cell chronic lymphocytic leukemia, or B-CLL, in patients who have failed two types of treatment.

Campath is known outside the United States as MabCampath and is marketed by Germany's Bayer Schering Pharma AG. It is marketed in the United States by Bayer AG's U.S. affiliate, Bayer HealthCare Pharmaceuticals.

Genzyme makes the drug and Bayer markets it under a licensing agreement with Genzyme. Genzyme acquired Campath when it bought Ilex Oncology in 2004.



More from Reuters

Photo

GMAC to get $3.5 billion more in government aid

WASHINGTON (Reuters) - GMAC Financial Services is expected to get about $3.5 billion of additional U.S. government aid to help the troubled lender absorb mortgage losses, a financial industry source familiar with the matter said on Wednesday.

» More Top News
A sign informs passengers of a "High Risk of Terrorist Attack" at the departure security line at Reagan National Airport in Washington December 29, 2009. REUTERS/Kevin Lamarque (

Body scans are Obama's call

The Dutch are doing it. So what's taking the U.S. so long to make airport body scanners mandatory?  Full Article | Video 

U.S.
People walk past a branch of Bank of America in New York's financial district April 28, 2009. REUTERS/Brendan McDermid
Rolfe Winkler:

Move your money

Boycotting "too big to fail" banks is a great idea -- so long as investors remember that banks aren't the only ones responsible for the crisis.  Full Article 

    Commentary